Cempra (CEMP) Announces Positive Data from Solithromycin Phase 2 in Japan
Tweet Send to a Friend
Cempra, Inc. (Nasdaq: CEMP) is jointly developing solithromycin for the Japanese market in partnership with Toyama Chemical, a subsidiary of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE